These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32302615)

  • 21. [Pharmacology of HMG CoA reductase inhibitors (statins)].
    Kostner GM
    Wien Med Wochenschr; 1999; 149(5-6):120-4. PubMed ID: 10408002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [An updated overview of the high intensity lipid lowering therapy in high cardiovascular risk patients].
    Pedro-Botet J; Pintó X
    Clin Investig Arterioscler; 2016; 28(1):19-30. PubMed ID: 26657098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Lowering cholesterol: how low is low enough?].
    Czuriga I; Edes I
    Orv Hetil; 2006 Jul; 147(29):1349-56. PubMed ID: 16941825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid-lowering therapy. New and established agents reduce risk of cardiovascular events.
    Smith CR
    Postgrad Med; 2004 Mar; 115(3):29-30, 33-6. PubMed ID: 15038253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic determinants of response to statins.
    Peters BJ; Klungel OH; de Boer A; Maitland-van der Zee AH
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):977-83. PubMed ID: 19673675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms underlying pleiotropic effects of statins.
    Palaniswamy C; Selvaraj DR; Selvaraj T; Sukhija R
    Am J Ther; 2010; 17(1):75-8. PubMed ID: 19451808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
    Wojakowski W; Gmiński J
    Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.
    Barter PJ; Rye KA
    Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953
    [No Abstract]   [Full Text] [Related]  

  • 32. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
    Schachter M
    Fundam Clin Pharmacol; 2005 Feb; 19(1):117-25. PubMed ID: 15660968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HMG-Co A reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaque.
    Morishita R; Tomita N; Ogihara T
    Curr Drug Targets; 2002 Oct; 3(5):379-85. PubMed ID: 12182229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New drugs for the treatment of hypercholesterolaemia.
    Iglesias P; Díez JJ
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1777-89. PubMed ID: 14585054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase modulator: toward age- and sex-personalized medicine.
    Pallottini V
    Expert Opin Ther Pat; 2015; 25(10):1079-83. PubMed ID: 26135220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
    Marzilli M
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():3-9. PubMed ID: 21391728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Statins--the panacea of the turn of the century?].
    Lubiszewska B; Ruzyłło W
    Pol Arch Med Wewn; 2004 May; 111(5):617-24. PubMed ID: 15508815
    [No Abstract]   [Full Text] [Related]  

  • 38. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Change in the cholesterol metabolism associated with the combined inhibition of synthesis and absorption].
    Márk L; Paragh G
    Orv Hetil; 2007 Apr; 148(14):627-32. PubMed ID: 17403635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statin therapy-evidence beyond lipid lowering contributing to plaque stability.
    de Lorenzo F; Feher M; Martin J; Collot-Teixeira S; Dotsenko O; McGregor JL
    Curr Med Chem; 2006; 13(28):3385-93. PubMed ID: 17168712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.